Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Eplontersen in ATTR-CM
jRCT2071250030Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Open-label, single-arm trial of eplontersen in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Ionis Pharmaceuticals. Primary endpoints: Number of participants with adverse events (AE) and serious adverse events (SAE), Change from baseline in platelet count and 7 more. Started Jun 2025; status: recruiting.
02
Drugs
eplontersen
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2071250030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250030.